GLP1R and Alzheimer disease: Specifically, the reduction in body weight values was more marked among incident treatments of fixed-dose combination of metformin+SGLT2i (−2.4%), SGLT2i (−1.7%) and GLP1-RA (−1.6%) (p-values < 0.001) as compared with other AD groups.